Drug Trial Radar · NCT04522739
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Sep 6, 2022
Primary completion
Sep 23, 2025
Study completion Sep 23, 2025
Sponsor
- Lead sponsor
- Emory UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Alzheimer's Association
- First posted
- Aug 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate whether a blood pressure medication, spironolactone, can be tolerated by older African American adults that have memory and thinking problems, also called mild cognitive impairment (MCI). This study will also investigate the effect of spironolactone on memory and thinking abilities as measured by performance on cognitive tests, which are tests that measure memory and thinking skills. Participants will take spironolactone or a placebo for one year and will have 4 to 5 study visits during the study period.
Conditions
- Mild Cognitive Impairment
- Alzheimer Disease
Interventions
SpironolactoneDrug
Study participants will receive a 25 mg dose of spironolactone. Participants will take one capsule by mouth per day for 12 months.
PlaceboDrug
A placebo to match spironolactone will be taken orally once per day for 12 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Count of Adverse EventsTime frame: Month 12
- Number of Participants Not Completing The StudyTime frame: Month 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Emory Clinic at Executive Park
Atlanta, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.